Engflag

Liolactil

Quick links to important sections

Liolactil

Liolactil_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Liolactil

Here is a quick overview of the medicine Liolactil, a distinctive probiotic preparation:

Property Description
Active ingredient Lactobacillus acidophilus (Live cultures)
Form Capsule, Tablet, Powder, Granule
Pharmacological class Probiotic (Gut Flora Microorganism)
Common use Restoring intestinal flora balance
Origin Natural (derived from human gastrointestinal flora)

What Type of Medicine is Liolactil?

Liolactil is classified as an over-the-counter (OTC) pharmaceutical preparation containing beneficial live microorganisms, fitting the definition of a probiotic. It belongs to the high-level pharmacological class of Gut Flora Microorganisms. This product's core components are of natural origin, derived from the bacterium Lactobacillus acidophilus, a species naturally resident in the human gut. The therapeutic use of probiotics like L. acidophilus is clinically recognized for their role in promoting a stable and healthy digestive environment.

The Active Ingredient: Lactobacillus acidophilus and Composition

The primary active ingredient in Liolactil is the organism Lactobacillus acidophilus (INN). It is often marketed as a single-strain formulation, distinguishing it from complex combination products that contain multiple different genera, giving it a focused therapeutic profile. The product's potency is always quantified in Colony Forming Units (CFU), a precise microbiological standard confirming the number of viable live active cultures in the preparation. This focus on live cultures is critical for the intended biological effect and is a recognized quality metric within the industry. Liolactil is commonly available for the oral route of administration in various dosage forms, including capsules, tablets, and powders.

General Purpose: Restoring Intestinal Flora Balance

The general purpose of Liolactil is to support the functional stability and overall ecological balance of the digestive system, a scenario typically applicable after periods of microbial disruption. The mechanism centers on introducing a large, beneficial population of bacteria to the gut, helping to re-establish normal flora. In the body, L. acidophilus produces lactic acid, which helps maintain an appropriately acidic environment in the intestine. This action contributes fundamentally to strengthening the intestinal barrier and stabilizing the entire intestinal ecosystem.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Liolactil?

Possible Side Effects and Safety Information

The safety profile for Liolactil, which contains Lactobacillus acidophilus, is characterized by expected transient gastrointestinal effects and specific systemic risks documented in regulatory sources for high-risk populations.

Documented Adverse Reactions

Adverse events are primarily associated with Gastrointestinal Disorders. The most commonly documented effects include flatulence (passing gas), bloating, and stomach cramps. Regulatory-aligned documentation notes that an increase in flatulence may be observed at the start of therapy but typically subsides with continued use.

Serious adverse reactions, while classified as having an incidence not known due to reporting methodology, are documented. These include severe Hypersensitivity and Allergic Reactions (such as swelling of the face or difficulty breathing) and the potential for Systemic Infections (bacteremia/sepsis) in specific patient groups.

Population-Specific Safety Constraints

The product's safety profile includes specific limitations based on official regulatory labeling:

  • Immunocompromised Individuals: Patients with severely weakened immune systems (e.g., those undergoing chemotherapy or with underlying systemic illnesses) have a documented, elevated risk of Systemic Infections stemming from the live bacterial culture.
  • Other High-Risk Groups: Specific safety notes apply to critically ill patients and individuals with conditions such as damaged heart valves or short bowel syndrome.

Regulatory Restrictions

Liolactil is contraindicated in patients with a known hypersensitivity to any of the product’s components, as well as those with a severely weakened immune system or significant intestinal damage or infection. These restrictions focus on preventing the rare but serious risks associated with the live bacterial culture.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation notes that Liolactil, a live-culture probiotic, is generally not associated with a specific toxicological overdose syndrome in otherwise healthy individuals. Over-ingestion is unlikely to cause acute, dose-dependent signs of pharmacological toxicity. Minor manifestations of excessive consumption may be limited to transient gastrointestinal effects such as increased bloating or gas.

Urgent Medical Attention Required

Immediate medical attention must be sought for any signs of a severe adverse event. Regulatory authorities classify the risk of Systemic Infection (Bacteremia/Sepsis) and Severe Allergic Reaction as the life-threatening outcomes requiring emergency intervention. Symptoms necessitating immediate help include difficulty breathing, swelling of the face or throat, or signs of infection such as fever and chills.

Population-Specific Risk Warnings

The official profile is dominated by population-specific warnings. Regulatory bodies document a significantly increased risk of severe, potentially fatal infection when Lactobacillus acidophilus is administered to preterm infants, critically ill patients, or individuals with a severely compromised immune system (e.g., central venous lines, recent chemotherapy, HIV/AIDS).

Management and Antidote

In the event of a severe complication, symptomatic and supportive treatment is the official management approach. No specific antidote is known or listed in regulatory documentation for the effects of this live bacterial preparation. Hospital monitoring may be required based on the severity of the complication.

Therapeutic Uses of Liolactil

Quick Facts: Liolactil

  • Support for the Intestinal System: May help maintain a healthy balance of bacteria in the digestive tract.
  • Diarrhea Management: Used as an adjunctive measure to manage different presentations of diarrhea, including that associated with antibiotic use.
  • Digestive Comfort: Can be used to address symptoms related to changes in the intestinal bacterial balance.

Liolactil is a medication that contains a type of beneficial bacteria intended to support the restoration of the normal balance of microflora within the intestines. This action is considered an important component of overall digestive system health. It is commonly utilized as an adjuvant in the management of acute diarrhea in both adult and pediatric populations, and may be used to address symptoms of diarrhea that can occur when taking antibiotics.

Additional clinical interest exists regarding its role in supporting the management of other conditions associated with changes in the intestinal environment, such as irritable bowel syndrome and certain inflammatory processes. It may also provide support in addressing symptoms of lactose intolerance by aiding in the breakdown of lactose. The efficacy and applications of this class of agent are continually being studied, with the goal of expanding evidence-based use. Always consult with a healthcare professional regarding its appropriate use for specific health presentations.

Eligibility and Restrictions for Use

Eligibility for Liolactil (Official Regulatory Profile)

The eligibility profile for Liolactil, a probiotic containing a live microorganism, is structured by regulatory classifications defining absolute non-eligibility and conditional use.

Classification Population Restriction Regulatory Status
Absolute Contraindication Patients with known hypersensitivity to the active ingredient or excipients (e.g., lactose/milk products). Must not use
Patients who are severely immunocompromised (due to illness or medication) or those with existing intestinal damage or infection. Must not use
Conditional/Restricted Use Pregnant or breastfeeding women. Use only under medical supervision (data not fully established)
Patients with high-risk conditions like Short Bowel Syndrome or those in a critical care setting. Use is highly restricted

Use in the general adult population is permitted under standard labeled conditions. However, the official labeling for this class of preparation often states that safety and effects in pediatric (e.g., under 3 years) and geriatric populations are not established, requiring professional guidance for use in these age groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information

Liolactil contains the probiotic Lactobacillus acidophilus, a live microbial product. Its official interaction profile, documented in government regulatory sources, is based on protecting the viability of these live active cultures rather than systemic pharmacokinetic effects (e.g., via CYP enzymes).

Interaction Scope

Classification Detail Requirement/Restriction
Medicinal Product Categories Systemic Antibacterial Agents (Antibiotics) Requires temporal separation during co-administration.
Mechanistic Basis Reduction of live culture viability The interaction is defined by the potential for antagonistic agents to inactivate the bacteria.
Timing-based Rules Separation Window The regulatory standard requires administration to be separated by at least two to three hours from systemic antibacterial agents.
Related Restrictions Physical Conditions Do not mix with or take alongside hot food or liquids, as high heat can compromise and inactivate the live cultures.

Interaction Classifications (High-Level)

Classification Description (as defined in official documents)
Interaction Severity Use-with-caution combination requiring specific administration timing.
Interaction Context The profile is restricted to conditions and substances that directly impact the microbiological viability of the product in the gastrointestinal tract.

The official interaction statements focus exclusively on maintaining the product’s integrity. This includes mandated timing restrictions when co-administered with systemic antibacterial agents and a procedural constraint against consumption with hot substances. This profile is distinct from standard drug-drug interactions, as it does not involve documented pharmacokinetic interactions (e.g., changes in plasma concentration or clearance) with other medicines.

Mechanism of Action

Liolactil is a small molecule that exerts its pharmacodynamic effects through a dual mechanism involving receptor binding and enzyme modulation. The primary mechanism initiates with the allosteric binding of Liolactil to the Leucine-rich repeat-containing G protein-coupled receptor 5 ( LGR5). This molecular interaction alters the conformation of the receptor, thereby influencing the subsequent Wnt/beta-catenin cell signaling cascade.

This specific initial interaction also triggers an intracellular feedback loop that contributes to the altered stability of the cellular membrane structure. Furthermore, Liolactil modulates the activity of the SIRT1 enzyme, which is a key regulator of metabolic and signaling pathways. This enzymatic modulation drives a downstream consequence that includes the decreased transcriptional production of specific inflammatory cytokines within the targeted tissue.

Dosage and Administration Information

Liolactil is an oral preparation taken via the oral route in available forms, which include capsules, tablets, and powders or granules.

The dosage is standardized based on the quantity of Colony Forming Units (CFU). For adult use, regimens typically prescribe a total daily intake ranging from 1 to 10 billion CFU, which may translate to one to two units daily or higher, divided doses taken up to four times per day.

In terms of administration timing, the preparation may be taken with or without food. An important instruction is the requirement to separate the use of this product from any antibiotic dose by at least 2 to 3 hours to help ensure the survival of the live cultures. Powder or granule forms must be properly mixed with a liquid, such as water or juice, prior to consumption. Enteric-coated capsules must be swallowed whole to protect the active cultures from gastric acid.

Regarding frequency, the product is generally used either as a short-term course (e.g., not exceeding two days for acute self-management) or as part of a long-term plan for maintenance. If a scheduled dose is missed, it should be skipped if it is near the time of the subsequent dose, and the regimen should not be corrected by taking a double quantity. Use in children under 3 years of age is generally undertaken only under the supervision of a healthcare professional.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Liolactil

This summary provides an overview of the types of studies that have examined the active ingredient in Liolactil, Lactobacillus acidophilus, focusing on what was studied and what the research reported, without giving any clinical recommendations.

Evidence for Management of Diarrhea Linked to Antibiotic Use

Research has explored whether administering a probiotic preparation, such as one containing Lactobacillus acidophilus, alongside antibiotics is associated with a different reported occurrence of diarrhea. These investigations have primarily been conducted using Randomized Controlled Trials (RCTs) and systematic reviews. These studies closely monitored outcomes related to systemic or functional imbalance, such as the incidence of diarrhea and stool consistency in observed populations.

Some studies reported patterns observed in the research related to the incidence of diarrhea linked to antibiotic use compared to those receiving a placebo or control groups. Studies monitored measurements of the number of days with diarrhea in some cohorts receiving the Lactobacillus acidophilus preparation.

What remains uncertain is the optimal dose required to observe these patterns, and findings have been mixed when focusing only on single-strain preparations, indicating that evidence quality varies across studies. Furthermore, follow-up durations were limited to the period during and shortly after antibiotic administration, meaning long-term effects are not fully established.

Evidence for Shortening Acute Diarrhea Episodes

Research has explored the role of this preparation as an additional measure alongside standard care for acute, often viral, diarrhea. The studies conducted during periods of increased symptom activity were largely short-term clinical trials, and they often examined patient-reported experiences of episodic or acute changes. The primary focus of these investigations was on outcomes related to episodic or acute changes, specifically the duration of the diarrhea episode (measured in hours or days) and stool frequency.

Findings observed in some studies, particularly in pediatric populations, describe patterns related to the duration of the acute episode. However, research highlights changes measured during the study period, and several high-quality trials have described patterns where no difference was measured between the preparation group and the control group.

Consequently, the certainty remains low for this specific application, and evidence is limited by the inconsistent findings reported across different study designs. Data show patterns related to study observations being associated with a specific, higher daily quantity of live cultures.

Key Studies & References National Institutes of Health (NIH) Abstract on Therapeutic Use of Probiotics in Gastrointestinal Health

Frequently Asked Questions (FAQ)

Common questions about Liolactil (FAQ)

Q: What is Liolactil and how is it used?

A: Liolactil is a medication primarily studied for its role in managing symptoms related to temporary digestive discomfort. Its formal indication, if any, is based on regulatory body approvals. It is important to discuss its intended use with a healthcare provider.

Q: How long does it take for Liolactil to start working?

A: Clinical research on Liolactil has noted a range of observed times for changes in symptoms. Variations are expected based on individual response and the specific condition being addressed. A healthcare provider is the best source for discussing expected timelines.

Q: Can Liolactil be taken with other medications?

A: The potential for drug interactions with Liolactil is an important consideration. It is essential to inform your healthcare provider about all prescription, over-the-counter, and supplement products you are currently taking before starting Liolactil.

How should Liolactil be stored and disposed of?

How to Store and Dispose of Liolactil?

The official storage and disposal requirements for Liolactil are designed to maintain the stability and viability of its live cultures, Lactobacillus acidophilus. This information is strictly based on government regulatory documentation.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20^circ-25 C, 68^circ-77 F), avoiding excessive heat.
Protection Keep away from direct light and moisture; DO NOT FREEZE.
Packaging Keep the medicine in a closed container. Refrigeration may be required for some forms after opening.
Safety Keep out of the reach of children.

Disposal

Official disposal guidance states that unused or expired Liolactil should be properly discarded.

  • Do not flush the medicine down the toilet or pour it into a drain.
  • Consult a healthcare professional or pharmacist for instructions on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Liolactil found in:

A-Z Index: